A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2017
At a glance
- Drugs C2N 8E12 (Primary)
- Indications Progressive supranuclear palsy
- Focus Adverse reactions; Therapeutic Use
- Sponsors AbbVie
- 12 Oct 2017 Planned End Date changed from 4 Sep 2019 to 3 Sep 2019.
- 20 Jul 2017 Study design presented at the Alzheimer's Association International Conference 2017.
- 03 Jan 2017 Status changed from not yet recruiting to recruiting.